Overview

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Status:
RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
To find a recommended dose of HC-7366 to patients with AML. The safety and effects of this drug combination will also be studied.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
HiberCell, Inc.